Ruti Aga Handed Six-Year Ban: A Family Member's Forged Prescription Writes the Obituary of a Marathon Career

Ethiopian marathon runner Ruti Aga has been banned for six years by the Athletics Integrity Unit (AIU). According to the agency's statement issued on Thursday, the six-year sanction is built from two separate violations. The first is a presence violation involving the prohibited substance methylprednisolone, which carries two years. The second is tampering — submitting a forged prescription to mislead investigators — which carries four years. Added together, that makes six. The ban is dated from 10 September, the same date on which Aga was provisionally suspended. Under the rules, time served under provisional suspension counts against the sanction, so this is a procedural benefit rather than any kind of leniency. The first thing that needs saying is that doping is not the real story here. The real story is that an athlete with Major credentials behind her — Berlin, Tokyo — got caught in the trap of presenting a defence that was entirely fabricated. And that fabricated defence converted what might have been a two-year absence into the end of a career. The sequence runs like this. In March this year Aga won a half marathon in China. A sample collected at that race returned an adverse finding for methylprednisolone. She was provisionally suspended from 10 September. During the investigation she explained the finding by citing a knee injury and produced a prescription as evidence of treatment. When the AIU checked the prescription, the clinic named on it turned out not to exist. The person who had written it as a 'doctor' was a family member with no medical registration. Questioned about it, that person claimed to have used 'an old prescription pad from a former workplace' — and the clinic in question explicitly disowns that claim. Three independent verification failures in a single document. Now the point that has been most badly mangled in coverage of this case. The original report described methylprednisolone as a 'prohibited steroid' and stated that WADA classes it as performance enhancing. That is technically wrong. Methylprednisolone is a glucocorticoid, not an anabolic steroid. On the WADA Prohibited List it sits in class S9, whereas anabolic steroids sit in class S1. And the distinction is not semantic — it changes the legal hinge of the entire case. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. The direct consequence is that a therapeutic knee injection given out of competition is entirely lawful, and becomes a violation only if residues are still present in-competition. That is why the real fight in this case was never about 'steroid use'. It was about route of administration and timing relative to the race. In road running the testing window opens at 23:59 on the day before the race. So an injection given days earlier that leaves residue behind becomes a violation even where the treatment itself was legitimate. Aga had a valid pathway here. Intra-articular or peri-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners. With genuine medical records she could have argued timing and route and pushed the matter toward a no-fault or no-significant-fault finding, where the sanction could have been a reprimand or a substantially reduced period. Presenting a forged document closed that pathway permanently. This is the bitterest paradox of the case: an athlete who could have been saved by the truth buried herself with a lie. The arithmetic of two plus four tells its own story. The two years attach to the presence violation — the prohibited substance being in her body. That is consistent with a Specified Substance finding where deliberate cheating was not established. The four years attach to tampering, which is the standard sanction under the World Anti-Doping Code. The sum makes clear that the panel accepted no mitigation on Aga's behalf. Had it found no significant fault, the presence sanction could have been reduced. A forged prescription makes such a finding logically impossible. There is a further subtlety. Forged documentation is itself circumstantial evidence of an intent to conceal, yet it did not aggravate the presence sanction — it was kept in a separate category. The panel treated the two violations as independent, sanctioned each separately, and then combined them. That is consistent with the Code's architecture, but it sends the message that documentary deception costs more than twice what the underlying presence violation costs. In career terms this sanction is functionally a lifetime ban. Aga is 32. When she returns she will be nearly 38. The depth of Ethiopian women's marathoning is such that a 38-year-old with a doping record on her file is essentially unselectable for a national team. The 2028 Olympic cycle is gone entirely, and beyond it there is no realistic route back. Her sporting legacy is now bifurcated. On one side sits the 2026 Tokyo Marathon title and three second-place finishes at World Marathon Majors — the record of a genuinely elite marathoner. On the other sits a six-year ban that makes her commercially radioactive. Distance-running sponsorship is already thin, and no brand will take on a doping record. One important gap: the AIU statement does not specify the scope of disqualification. Standard practice voids the result and prize money from the competition at which the sample was collected, but results before that date — including the 2026 Tokyo title — are not automatically annulled absent evidence of earlier use. Now the part that takes this beyond an individual sanction. The 'doctor' in Aga's case was a family member with no medical registration. That is not a clerical error; it is the signature of an athlete operating without a credentialed team physician. A runner whose knee treatment was documented and whose medical need was established had two options. One, hold or apply for a Therapeutic Use Exemption. Two, observe WADA's route-specific washout period. Neither appears to have happened. And the sharpest testimony to that is that a forged prescription was manufactured in place of real records. It is also worth noting that the four-year tampering sanction came not from a document alone but from an interview. Statements Aga made under questioning became part of the basis for the sanction. Language and translation conditions in AIU interviews with African athletes have been a recurring point of contention. Questions may be raised about how that interview was conducted, although no formal allegation along those lines has surfaced so far. The root cause of the whole affair is the knee injury, and that is a systemic signal rather than an individual one. Injured marathoners face heavy pressure to mask pain in order to protect appearance fees and sponsorship. Glucocorticoids are the cheapest and most readily available tool for doing so. And where the surrounding medical network is informal, fabricating a prescription becomes the downstream product of that governance gap. The forged document is a symptom, not the cause. One further piece of context matters. The March race at which the sample was collected was a Label road race in China, where African elite fields are deep and appearance-fee budgets are large. That same tier is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races. The Chinese half-marathon circuit has long been an attractive, low-risk income tier for East African marathoners between Majors — and it is now the most closely scrutinised tier of all. More broadly, AIU enforcement is shifting from 'detection' toward 'document verification'. Aga's case is not an outlier; it belongs to a recognisable family of East African road-racing cases in which an initial substance violation is compounded by a fabricated or altered explanation. And because the same informal medical networks serve many athletes in the same training clusters, more cases of this profile are likely in the pipeline. The sanction will be contested in argument. Six years for a substance with no proven endurance benefit is a striking outcome. It will be cited both as evidence of AIU rigour and as evidence of disproportionate enforcement against African road runners. Both readings have something behind them. On one hand, a forged document is a serious offence in any system and demands severity. On the other, it is fair to ask whether a de facto lifetime ban on a 32-year-old is proportionate to an offence that delivered no performance gain to anyone. What comes next? An appeal to the Court of Arbitration for Sport is open, with a window that typically runs about 21 days from the reasoned decision. But the forgery finding rests on documentary evidence, and such findings are very hard to overturn. There is also potential criminal exposure at national level over document forgery, though that sits outside AIU jurisdiction and no action on that front has surfaced. One thing the reporting does not state clearly is the year of the March race or the year in which the ban will expire. The language of the statement implies both relate to the current year, but precise dates are not given. Likewise her finishing time, splits and the strength of the field are absent, so any judgment about her form would be speculation. What is known is that she won the race — which suggests an elite field and in-competition testing were present. The lessons sit at three levels. At the athlete level: with correct paperwork and correct timing, there may have been no case at all. At the management level: an agent or team that cannot connect its athlete to a credentialed physician becomes complicit, whether or not charges follow. At the system level: where demand for cheap, fast treatment is high and formal medicine is neither cheap nor accessible, forged prescriptions will be produced. Punishing athletes alone will not dry up that root. Finally, the saddest aspect of this case is that Aga technically had a real defence available. Methylprednisolone is a glucocorticoid, prohibited in-competition only, and its therapeutic use for knee injury is entirely lawful. With genuine medical records she could have walked out of this case. She did not take that route. She chose fake paper — and that single decision placed the shine of the 2026 Tokyo title under a permanent shadow of doubt.